Home NASDAQ: MDWD
loading

MediWound Ltd. - Ordinary Share Stock (MDWD) Latest News

thumbnail
pulisher
Zacks Investment Research

MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?

thumbnail
pulisher
Benzinga

HC Wainwright & Co. Maintains Buy Rating for MediWound: Here's What You Need To Know

thumbnail
pulisher
GlobeNewswire Inc.

MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

thumbnail
pulisher
Benzinga

What 4 Analyst Ratings Have To Say About MediWound

thumbnail
pulisher
Zacks Investment Research

MediWound (MDWD) Q2 Earnings and Revenues Beat Estimates

thumbnail
pulisher
GlobeNewswire Inc.

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

thumbnail
pulisher
GlobeNewswire Inc.

MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study

thumbnail
pulisher
GlobeNewswire Inc.

MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study

thumbnail
pulisher
Zacks Investment Research

Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates

thumbnail
pulisher
Zacks Investment Research

Verve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue Estimates

thumbnail
pulisher
Zacks Investment Research

Zoetis (ZTS) Beats Q2 Earnings and Revenue Estimates

thumbnail
pulisher
GlobeNewswire Inc.

MediWound Announces Commercial Launch of NexoBrid® in Japan

thumbnail
pulisher
GlobeNewswire Inc.

MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

thumbnail
pulisher
GlobeNewswire Inc.

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design

thumbnail
pulisher
GlobeNewswire Inc.

MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023

thumbnail
pulisher
Zacks Investment Research

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

thumbnail
pulisher
GlobeNewswire Inc.

MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Cap:     |  Volume (24h):